Feng J Xu from New York, NY, age 58

Lawyers & Attorneys

Feng Xu, New York NY - Lawyer

view source

Address:

Fitzpatrick Cella Harper & Scinto
30 Rockefeller Plaza, New York, NY 10112
2122182919 (Office), 2122182200 (Fax)

Licenses:

Connecticut - Active 2005
New York - Currently registered 2006

Education:

University of Connecticut School of Law
Degree - JD - Juris Doctor - Law
Graduated - 2004
Florida State University
Degree - PhD - Doctorate - Biochemistry
Graduated - 1997
Wuhan University
Degree - MS - Master of Science - Polymer Chemistry
Graduated - 1987
Wuhan University
Degree - BS - Bachelor of Science
Graduated - 1984

Specialties:

Litigation - 100%

Associations:

American Bar Association
American Chemical Society

Feng Xu, Ph.D., New York NY - Lawyer

view source

Office:

Fitzpatrick, Cella, Harper & Scinto
1290 Avenue Of The Americas, New York, NY

Specialties:

Litigation
Patent Prosecution
PTO Contested Proceedings

ISLN:

918811576

Admitted:

2005

University:

Unlisted school, B.S.

Law School:

University of Connecticut School of Law, J.D.

Name / Title

Company / Classification

Phones & Addresses

Feng Xu
Director, Treasurer

Purally Water Co., Ltd

Feng Xu
Principal

Mingyu Group LLC
Nonclassifiable Establishments

83 Amelia Ave, Livingston, NJ 07039

Feng Xu

DIGITAL CONSULTING GROUP, INC

109 W 27 St 7, New York, NY 10001

Feng Xu
Treasurer

Sp Investments, Inc

12B Fuxing Rd, New York, NY 10081

Wikipedia References

Feng Xu

Work:

Feng Xu " Feng Xu " ( ) was an eunuch of the late Han Dynasty who served Emperor Ling of Han; He was also one of the Ten regular attendants ( also known as the Ten Eunuchs ) in the novel Romance of the Three Kingdoms....

Education:

Specialty:

Leader

Skills & Activities:

Master status:

Subordinate

Us Patents

Dihydroxy Open-Acid And Salts Of Hmg-Coa Reductase Inhibitors
view source
US Patent:

6569461, May 27, 2003
Filed:

Apr 26, 2000
Appl. No.:

09/558800
Inventors:

Richard D. Tillyer - Cranford NJ
Paul J. Reider - Westfield NJ
Edward J. J. Grabowski - Westfield NJ
Feng Xu - Staten Island NY
Jose M. Vega - Trappe PA
Mandana Asgharnejad - Ambler PA
Assignee:

Merck Co., Inc. - Rahway NJ
International Classification:

A61K 900
US Classification:

424497, 424400, 424464, 424465, 424482, 424490
Abstract:

The instant invention provides methods and pharmaceutical compositions for inhibiting HMG-CoA reductase, as well as for treating and/or reducing the risk for diseases and conditions affected by inhibition of HMG-CoA reductase, comprising orally administering a therapeutically effective amount of a compound selected from a dihydroxy open acid statin and a pharmaceutically acceptable salt or ester thereof in a delayed-release pharmaceutical dosage form to a patient in need of such treatment wherein substantial release of the compound from the dosage form is delayed until after passage of the dosage form through the stomach.

Preparation Of Sulfonyl Quinoline
view source
US Patent:

7009055, Mar 7, 2006
Filed:

Jul 19, 2002
Appl. No.:

10/484610
Inventors:

Feng Xu - Staten Island NY, US
Kimberly A. Savary - Rahway NJ, US
John M. Williams - Hillsborough NJ, US
Assignee:

Merck & Co., Inc. - Rahway NJ
International Classification:

C07D 215/16
US Classification:

546177, 546180, 568 34, 568 28
Abstract:

A dibromomethyl moiety is converted to a sulfonylmethyl moiety by treatment with a sulfinic acid salt. For example, (methyl-sulfonyl)methyl bromo-quinoline is prepared by the treatment of dibromomethyl bromo-quinoline with a sulfinic acid salt.

Process For Preparing Branched Ribonucleosides From 1,2-Anhydroribofuranose Intermediates
view source
US Patent:

7339054, Mar 4, 2008
Filed:

Feb 6, 2004
Appl. No.:

10/544575
Inventors:

Feng Xu - Staten Island NY, US
Matthew M Bio - London, GB
Cameron Cowden - Hoddesdon, GB
Kimberly A. Petrillo - Philadelphia PA, US
J. Michael Williams - Hillsborough NJ, US
Chunhua Yang - Edison NJ, US
Marjorie See Waters - Cranbury NJ, US
Assignee:

Merck & Co., Inc. - Rahway NJ
International Classification:

C07H 19/14
C07D 487/00
US Classification:

536 2711, 536 272, 544262
Abstract:

A process is provided for the preparation of branched-chain ribonucleosides of formula (I):.

Process For Preparing Chiral Dipeptidyl Peptidase-Iv Inhibitor Intermediates
view source
US Patent:

7902376, Mar 8, 2011
Filed:

Jan 22, 2009
Appl. No.:

12/321533
Inventors:

Feng Xu - Staten Island NY, US
Mary M. Kim - Cheltenham PA, US
Yoshinori Kohmura - Ibaraki, JP
Tricia Sladicka - Schenectady NY, US
Jonathan D. Rosen - Iowa City IA, US
Michael J. Zacuto - Jersey City NJ, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
Banyu Pharmaceutical Co., Ltd. - Tokyo
International Classification:

C07D 498/04
C07D 487/04
C07D 309/10
US Classification:

548218, 548242, 5483605, 549419
Abstract:

A novel process is provided for the preparation of chiral trans-2,3-disubstituted 5-oxotetrahydropyrans of structural formula (I):.

Polymorphic Forms Of A Gabaagonist
view source
US Patent:

8022084, Sep 20, 2011
Filed:

Jan 26, 2006
Appl. No.:

11/813796
Inventors:

Daniel J. Kumke - Rahway NJ, US
Jerry A. Murry - Rahway NJ, US
Bryon L. Simmons - Rahway NJ, US
Feng Xu - Rahway NJ, US
Assignee:

H. Lundbeck A/S - Valby
International Classification:

A61K 31/4355
C07D 498/04
US Classification:

514302, 546116
Abstract:

The present invention is directed to novel polymorphic forms of the compound 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrate (gaboxadol monohydrate). The invention is further concerned with pharmaceutical compositions containing the polymorphic forms as an active ingredient, methods for treatment of disorders susceptible to amelioration by GABAA receptor agonism with the polymorphic forms, and processes for the preparation of the polymorphic forms.

Polymorphic Forms Of A Gabaa Agonist
view source
US Patent:

8193216, Jun 5, 2012
Filed:

Aug 16, 2011
Appl. No.:

13/210908
Inventors:

Daniel J. Kumke - Colts Neck NJ, US
Jerry A. Murry - Thousand Oaks CA, US
Bryon L. Simmons - Hamilton NJ, US
Feng Xu - Staten Island NY, US
Assignee:

H. Lundbeck A/S - Valby
International Classification:

A61K 31/4355
C07D 498/04
US Classification:

514302, 546116
Abstract:

The present invention is directed to novel polymorphic forms of the compound 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrate (gaboxadol monohydrate). The invention is further concerned with pharmaceutical compositions containing the polymorphic forms as an active ingredient, methods for treatment of disorders susceptible to amelioration by GABAA receptor agonism with the polymorphic forms, and processes for the preparation of the polymorphic forms.

Dihydroxy Open-Acid Salt Of Simvastatin
view source
US Patent:

20030176501, Sep 18, 2003
Filed:

Nov 13, 2002
Appl. No.:

10/293153
Inventors:

Richard Tillyer - Cranford NJ, US
Paul Reider - Westfield NJ, US
Edward Grabowski - Westfield NJ, US
Feng Xu - Staten Island NY, US
Robert Wenslow - East Windsor NJ, US
Jose Vega - Trappe PA, US
Richard Varsolona - Scotch Plains NJ, US
International Classification:

C07C069/34
A61K031/225
US Classification:

514/548000, 560/146000
Abstract:

The instant invention provides methods and pharmaceutical compositions for inhibiting HMG-CoA reductase, as well as for treating and/or reducing the risk for diseases and conditions affected by inhibition of HMG-CoA reductase, comprising orally administering a therapeutically effective amount of a crystalline hydrated form of the calcium salt of dihydroxy open acid simvastatin to a patient in need of such treatment. Methods for making the calcium salt of dihydroxy open acid simvastatin are also provided.

Dihydroxy Open-Acid And Salts Of Hmg-Co-A Reductase Inhibitors
view source
US Patent:

20030211151, Nov 13, 2003
Filed:

Apr 29, 2003
Appl. No.:

10/425154
Inventors:

Richard Tillyer - Cranford NJ, US
Paul Reider - Westfield NJ, US
Edward Grabowski - Westfield NJ, US
Feng Xu - Staten Island NY, US
Jose Vega - Trappe PA, US
Mandana Asgharnejad - Ambler PA, US
Assignee:

Merck & Co., Inc.
International Classification:

A61K031/225
A61K009/22
A61K009/16
A61K009/50
US Classification:

424/468000, 514/548000
Abstract:

The instant invention provides methods and pharmaceutical compositions for inhibiting HMG-CoA reductase, as well as for treating and/or reducing the risk for diseases and conditions affected by inhibition of HMG-CoA reductase, comprising orally administering a therapeutically effective amount of a compound selected from a dihydroxy open acid statin and a pharmaceutically acceptable salt or ester thereof in a delayed-release pharmaceutical dosage form to a patient in need of such treatment wherein substantial release of the compound from the dosage form is delayed until after passage of the dosage form through the stomach.